Published in Mol Cell Neurosci on November 09, 2007
Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). Trends Immunol (2009) 1.96
β-catenin signaling: a novel mediator of fibrosis and potential therapeutic target. Curr Opin Rheumatol (2011) 1.41
Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther (2010) 1.39
GSK-3β: A Bifunctional Role in Cell Death Pathways. Int J Cell Biol (2012) 1.21
GSK-3 as a Target for Lithium-Induced Neuroprotection Against Excitotoxicity in Neuronal Cultures and Animal Models of Ischemic Stroke. Front Mol Neurosci (2011) 1.14
Overexpression of glycogen synthase kinase 3beta sensitizes neuronal cells to ethanol toxicity. J Neurosci Res (2009) 1.02
GSK3beta in ethanol neurotoxicity. Mol Neurobiol (2009) 1.01
Mood stabilizer-regulated miRNAs in neuropsychiatric and neurodegenerative diseases: identifying associations and functions. Am J Transl Res (2013) 0.92
Lithium-mediated protection against ethanol neurotoxicity. Front Neurosci (2010) 0.91
Regulation by glycogen synthase kinase-3 of inflammation and T cells in CNS diseases. Front Mol Neurosci (2011) 0.90
Deregulation of Tpl2 and NF-kappaB signaling and induction of macrophage apoptosis by the anti-depressant drug lithium. Cell Signal (2008) 0.84
Glycogen synthase kinase-3 (GSK-3) regulates TGF-β₁-induced differentiation of pulmonary fibroblasts. Br J Pharmacol (2013) 0.84
Preclinical and clinical investigations of mood stabilizers for Huntington's disease: what have we learned? Int J Biol Sci (2014) 0.82
DNA modification study of major depressive disorder: beyond locus-by-locus comparisons. Biol Psychiatry (2014) 0.81
Potential application of lithium in Parkinson's and other neurodegenerative diseases. Front Neurosci (2015) 0.81
The TGF-β pathway is activated by 5-fluorouracil treatment in drug resistant colorectal carcinoma cells. Oncotarget (2016) 0.79
Potential molecular and cellular mechanism of psychotropic drugs. Clin Psychopharmacol Neurosci (2014) 0.79
Neuron membrane trafficking and protein kinases involved in autism and ADHD. Int J Mol Sci (2015) 0.78
Intracerebroventricular administration of ouabain alters synaptic plasticity and dopamine release in rat medial prefrontal cortex. J Neural Transm (Vienna) (2013) 0.76
The Neuroprotective Effect of Lithium in cannabinoid Dependence is Mediated through Modulation of Cyclic AMP, ERK1/2 and GSK-3β Phosphorylation in Cerebellar Granular Neurons of Rat. Iran J Pharm Res (2015) 0.75
Systems Genetic Analyses Highlight a TGFβ-FOXO3 Dependent Striatal Astrocyte Network Conserved across Species and Associated with Stress, Sleep, and Huntington's Disease. PLoS Genet (2016) 0.75
Antifibrotic Actions of Peroxisome Proliferator-Activated Receptor γ Ligands in Corneal Fibroblasts Are Mediated by β-Catenin-Regulated Pathways. Am J Pathol (2017) 0.75
Dissecting the Molecular Mechanisms of Neurodegenerative Diseases through Network Biology. Front Aging Neurosci (2017) 0.75
Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell (2003) 25.94
Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature (2003) 20.48
Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) JAMA (1995) 13.37
Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature (1993) 11.54
A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A (1996) 11.37
Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science (1996) 9.12
The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev (1996) 7.78
Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol (1996) 6.88
The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol (2001) 6.12
p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci (2001) 5.74
Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science (2004) 4.74
CREB-binding protein and p300 in transcriptional regulation. J Biol Chem (2001) 4.67
Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci U S A (1995) 4.54
p21-activated kinases in cancer. Nat Rev Cancer (2006) 4.24
Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med (1998) 4.09
Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol (2001) 4.00
New insights into BDNF function in depression and anxiety. Nat Neurosci (2007) 3.94
CBP and p300: HATs for different occasions. Biochem Pharmacol (2004) 3.38
Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. Nature (1993) 3.23
Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci (2004) 3.12
Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature (1995) 3.06
PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3. Nat Cell Biol (2004) 2.91
Akt interacts directly with Smad3 to regulate the sensitivity to TGF-beta induced apoptosis. Nat Cell Biol (2004) 2.59
Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler Thromb Vasc Biol (1999) 2.56
Phosphorylation of CBP mediates transcriptional activation by neural activity and CaM kinase IV. Neuron (2002) 2.45
Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A (1999) 2.41
Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem (2003) 2.35
Lithium-induced increase in human brain grey matter. Lancet (2000) 2.31
Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation. Nature (1998) 2.25
Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat (2007) 2.21
Control of Smad7 stability by competition between acetylation and ubiquitination. Mol Cell (2002) 2.18
Tissue plasminogen activator contributes to the late phase of LTP and to synaptic growth in the hippocampal mossy fiber pathway. Neuron (1998) 2.13
CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J Neurochem (2001) 2.11
Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun (2001) 2.08
GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis. Cell (1998) 2.03
Interaction of human immunodeficiency virus type 1 Tat with the transcriptional coactivators p300 and CREB binding protein. J Virol (1998) 1.85
Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest (1991) 1.85
Tissue plasminogen activator induction in Purkinje neurons after cerebellar motor learning. Science (1995) 1.84
Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J (2003) 1.80
Tissue plasminogen activator in the amygdala is critical for stress-induced anxiety-like behavior. Nat Neurosci (2003) 1.72
The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. J Neurosci (2003) 1.71
Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry (1999) 1.66
Tissue plasminogen activator and plasminogen mediate stress-induced decline of neuronal and cognitive functions in the mouse hippocampus. Proc Natl Acad Sci U S A (2005) 1.59
Differential roles of glycogen synthase kinase-3 isoforms in the regulation of transcriptional activation. J Biol Chem (2006) 1.57
Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol Psychiatry (2004) 1.55
Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects? Biol Psychiatry (2000) 1.55
Tissue-type plasminogen activator: a multifaceted modulator of neurotransmission and synaptic plasticity. Neuron (2006) 1.54
Plasminogen activator-plasmin system and neuronal migration. Nature (1982) 1.50
Regulation and function of glycogen synthase kinase-3 isoforms in neuronal survival. J Biol Chem (2006) 1.48
Lithium neuroprotection: molecular mechanisms and clinical implications. Expert Rev Mol Med (2004) 1.44
Plasminogen activator secretion by granule neurons in cultures of developing cerebellum. Proc Natl Acad Sci U S A (1981) 1.43
Interaction between Smad7 and beta-catenin: importance for transforming growth factor beta-induced apoptosis. Mol Cell Biol (2005) 1.41
Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry (2004) 1.39
Stress-induced structural remodeling in hippocampus: prevention by lithium treatment. Proc Natl Acad Sci U S A (2004) 1.37
Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases? Crit Rev Neurobiol (2004) 1.34
Neuronal cell death and tPA. Nature (1996) 1.33
Neuronal migration is retarded in mice lacking the tissue plasminogen activator gene. Proc Natl Acad Sci U S A (1999) 1.26
The balance between acetylation and deacetylation controls Smad7 stability. J Biol Chem (2005) 1.24
Insulin-like growth factor-I inhibits transcriptional responses of transforming growth factor-beta by phosphatidylinositol 3-kinase/Akt-dependent suppression of the activation of Smad3 but not Smad2. J Biol Chem (2003) 1.23
Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol Ther (2002) 1.23
Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost (2005) 1.23
Emerging roles for TGF-beta1 in nervous system development. Int J Dev Neurosci (2005) 1.22
Activity-dependent formation of perforated synapses in cultured hippocampal neurons. Eur J Neurosci (1999) 1.15
Cyclic adenosine 3',5'-monophosphate-elevating agents inhibit transforming growth factor-beta-induced SMAD3/4-dependent transcription via a protein kinase A-dependent mechanism. Oncogene (2003) 1.14
Up-regulation of a serine protease inhibitor in astrocytes mediates the neuroprotective activity of transforming growth factor beta1. FASEB J (1998) 1.13
Transforming growth factor-beta signalling in brain disorders. Cytokine Growth Factor Rev (2005) 1.07
Younger, premenopausal women with major depressive disorder have more abdominal fat and increased serum levels of prothrombotic factors: implications for greater cardiovascular risk. Metabolism (2005) 1.06
Tgf-Beta pathway as a potential target in neurodegeneration and Alzheimer's. Curr Alzheimer Res (2006) 0.99
Lithium-mediated phosphorylation of glycogen synthase kinase-3beta involves PI3 kinase-dependent activation of protein kinase C-alpha. J Mol Neurosci (2004) 0.95
Fibrin is a regulator of Schwann cell migration after sciatic nerve injury in mice. Neurosci Lett (2003) 0.94
Smad3-dependent induction of plasminogen activator inhibitor-1 in astrocytes mediates neuroprotective activity of transforming growth factor-beta 1 against NMDA-induced necrosis. Mol Cell Neurosci (2002) 0.93
Retrograde regulation in the CNS; neuron-specific interpretations of TGF-beta signaling. Neuron (2004) 0.93
Lithium stabilizes the polarized lens epithelial phenotype and inhibits proliferation, migration, and epithelial mesenchymal transition. J Pathol (2006) 0.92
Tissue plasminogen activator as a modulator of neuronal survival and function. Biochem Soc Trans (2002) 0.91
A bimodal model of the mechanism of action of lithium. Mol Psychiatry (1999) 0.89
Molecular and cellular mechanisms underlying mood stabilization in bipolar disorder: implications for the development of improved therapeutics. Mol Psychiatry (2002) 0.88
BDNF stimulates expression, activity and release of tissue-type plasminogen activator in mouse cortical neurons. Eur J Neurosci (1999) 0.88
Deficient release of plasminogen activator inhibitor-1 from astrocytes triggers apoptosis in neuronal cells. Brain Res Mol Brain Res (2001) 0.86
Altered cAMP-dependent protein kinase subunit immunolabeling in post-mortem brain from patients with bipolar affective disorder. J Neurochem (2003) 0.85
The possible role of tissue-type plasminogen activator and the plasminogen system in the pathogenesis of major depression. Med Hypotheses (2005) 0.84
The TGF-beta1/upstream stimulatory factor-regulated PAI-1 gene: potential involvement and a therapeutic target in Alzheimer's disease. J Biomed Biotechnol (2006) 0.81
Intracellular lithium and cyclic AMP levels are mutually regulated in neuronal cells. J Neurochem (2004) 0.77
Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther (2007) 2.90
Meta-analysis of genome-wide association data identifies a risk locus for major mood disorders on 3p21.1. Nat Genet (2010) 2.46
Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem (2004) 2.21
Monoamine oxidase A gene promoter variation and rearing experience influences aggressive behavior in rhesus monkeys. Biol Psychiatry (2005) 1.81
Contribution of common genetic variants to antidepressant response. Biol Psychiatry (2012) 1.73
Gene expression and genetic variation data implicate PCLO in bipolar disorder. Biol Psychiatry (2010) 1.70
Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet (2013) 1.68
Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease. Neuropsychopharmacology (2011) 1.66
Postinsult treatment with lithium reduces brain damage and facilitates neurological recovery in a rat ischemia/reperfusion model. Proc Natl Acad Sci U S A (2003) 1.62
Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J Neurosci (2006) 1.61
Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci (2008) 1.58
Differential roles of glycogen synthase kinase-3 isoforms in the regulation of transcriptional activation. J Biol Chem (2006) 1.57
PET imaging with [11C]PBR28 can localize and quantify upregulated peripheral benzodiazepine receptors associated with cerebral ischemia in rat. Neurosci Lett (2006) 1.56
How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems. Neuropharmacology (2008) 1.56
Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem (2002) 1.55
Valproic acid attenuates blood-brain barrier disruption in a rat model of transient focal cerebral ischemia: the roles of HDAC and MMP-9 inhibition. J Cereb Blood Flow Metab (2010) 1.53
The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain. J Neurochem (2009) 1.53
Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev (2013) 1.52
Regulation and function of glycogen synthase kinase-3 isoforms in neuronal survival. J Biol Chem (2006) 1.48
Lithium neuroprotection: molecular mechanisms and clinical implications. Expert Rev Mol Med (2004) 1.44
Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther (2010) 1.39
Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int J Neuropsychopharmacol (2008) 1.38
GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev (2007) 1.36
Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology (2002) 1.34
Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome. Int J Neuropsychopharmacol (2010) 1.31
Valproic acid induces functional heat-shock protein 70 via Class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. J Neurochem (2009) 1.28
Angiotensin II AT1 receptor blockade ameliorates brain inflammation. Neuropsychopharmacology (2010) 1.21
Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. PLoS Med (2012) 1.19
Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia. Brain Res Mol Brain Res (2004) 1.18
Valproic acid, a mood stabilizer and anticonvulsant, protects rat cerebral cortical neurons from spontaneous cell death: a role of histone deacetylase inhibition. FEBS Lett (2003) 1.18
The mood stabilizers valproic acid and lithium enhance mesenchymal stem cell migration via distinct mechanisms. Neuropsychopharmacology (2010) 1.07
Mesenchymal stem cells primed with valproate and lithium robustly migrate to infarcted regions and facilitate recovery in a stroke model. Stroke (2011) 1.06
Chronic valproate treatment enhances postischemic angiogenesis and promotes functional recovery in a rat model of ischemic stroke. Stroke (2012) 1.01
Regulation of c-Jun N-terminal kinase, p38 kinase and AP-1 DNA binding in cultured brain neurons: roles in glutamate excitotoxicity and lithium neuroprotection. J Neurochem (2003) 1.01
A systematic eQTL study of cis-trans epistasis in 210 HapMap individuals. Eur J Hum Genet (2011) 1.00
Post-insult valproic acid-regulated microRNAs: potential targets for cerebral ischemia. Am J Transl Res (2012) 0.99
Lithium ameliorates neurodegeneration, suppresses neuroinflammation, and improves behavioral performance in a mouse model of traumatic brain injury. J Neurotrauma (2011) 0.99
Lentivirally mediated GSK-3β silencing in the hippocampal dentate gyrus induces antidepressant-like effects in stressed mice. Int J Neuropsychopharmacol (2010) 0.98
Potential roles of HDAC inhibitors in mitigating ischemia-induced brain damage and facilitating endogenous regeneration and recovery. Curr Pharm Des (2013) 0.97
Genetics of early-onset obsessive-compulsive disorder. Eur Child Adolesc Psychiatry (2010) 0.97
Overexpression and nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase in a transgenic mouse model of Huntington's disease. Mol Cell Neurosci (2003) 0.97
Functional MRI of delayed chronic lithium treatment in rat focal cerebral ischemia. Stroke (2008) 0.96
miR-15a and miR-16 regulate serotonin transporter expression in human placental and rat brain raphe cells. Int J Neuropsychopharmacol (2012) 0.94
A pharmacological analysis of mice with a targeted disruption of the serotonin transporter. Psychopharmacology (Berl) (2007) 0.94
Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: obsessive-compulsive disorder as an example of overlapping clinical and genetic heterogeneity. Philos Trans R Soc Lond B Biol Sci (2013) 0.94
Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models. Acta Pharmacol Sin (2011) 0.93
Mood stabilizer-regulated miRNAs in neuropsychiatric and neurodegenerative diseases: identifying associations and functions. Am J Transl Res (2013) 0.92
Histone deacetylase inhibition alters histone methylation associated with heat shock protein 70 promoter modifications in astrocytes and neurons. Neuropharmacology (2010) 0.92
Lithium reduces ischemia-induced hippocampal CA1 damage and behavioral deficits in gerbils. Brain Res (2007) 0.92
Lithium upregulates vascular endothelial growth factor in brain endothelial cells and astrocytes. Stroke (2008) 0.91
Lithium reduces BACE1 overexpression, β amyloid accumulation, and spatial learning deficits in mice with traumatic brain injury. J Neurotrauma (2012) 0.90
Cross-disorder genome-wide analyses suggest a complex genetic relationship between Tourette's syndrome and OCD. Am J Psychiatry (2014) 0.90
Valproic acid attenuates microgliosis in injured spinal cord and purinergic P2X4 receptor expression in activated microglia. J Neurosci Res (2013) 0.89
The genetics of panic disorder. J Med Genet (2011) 0.88
Bax inhibitor 1, a modulator of calcium homeostasis, confers affective resilience. Brain Res (2011) 0.88
Lithium-induced inhibition of Src tyrosine kinase in rat cerebral cortical neurons: a role in neuroprotection against N-methyl-D-aspartate receptor-mediated excitotoxicity. FEBS Lett (2003) 0.87
Neuroprotective action of lithium in disorders of the central nervous system. Zhong Nan Da Xue Xue Bao Yi Xue Ban (2011) 0.87
Posttrauma cotreatment with lithium and valproate: reduction of lesion volume, attenuation of blood-brain barrier disruption, and improvement in motor coordination in mice with traumatic brain injury. J Neurosurg (2013) 0.87
The catechol-O-methyl transferase (COMT) gene and its potential association with schizophrenia: findings from a large German case-control and family-based sample. Schizophr Res (2010) 0.87
Altered 5-HT2C receptor agonist-induced responses and 5-HT2C receptor RNA editing in the amygdala of serotonin transporter knockout mice. BMC Pharmacol (2011) 0.87
Increased gene expression of diacylglycerol kinase η in bipolar disorder. Int J Neuropsychopharmacol (2010) 0.86
Potent neuroprotective effects of novel structural derivatives of valproic acid: potential roles of HDAC inhibition and HSP70 induction. Neurosci Lett (2010) 0.84
Common and rare alleles of the serotonin transporter gene, SLC6A4, associated with Tourette's disorder. Mov Disord (2013) 0.83
Susceptibility of striatal neurons to excitotoxic injury correlates with basal levels of Bcl-2 and the induction of P53 and c-Myc immunoreactivity. Neurobiol Dis (2005) 0.83
A reappraisal of the association between Dysbindin (DTNBP1) and schizophrenia in a large combined case-control and family-based sample of German ancestry. Schizophr Res (2010) 0.83
Rare missense neuronal cadherin gene (CDH2) variants in specific obsessive-compulsive disorder and Tourette disorder phenotypes. Eur J Hum Genet (2013) 0.81
[Neuroprotective actions of lithium]. Seishin Shinkeigaku Zasshi (2003) 0.79
Nuclear factor-kappaB-dependent cyclin D1 induction and DNA replication associated with N-methyl-D-aspartate receptor-mediated apoptosis in rat striatum. J Neurosci Res (2007) 0.79
Consideration of the BDNF gene in relation to two phenotypes: hoarding and obesity. J Abnorm Psychol (2011) 0.79
Neuroprotective effects of the mood stabilizer lamotrigine against glutamate excitotoxicity: roles of chromatin remodelling and Bcl-2 induction. Int J Neuropsychopharmacol (2012) 0.77
Genetic susceptibility for bipolar disorder and response to antidepressants in major depressive disorder. Am J Med Genet B Neuropsychiatr Genet (2013) 0.77
A systematic association mapping on chromosome 6q in bipolar affective disorder--evidence for the melanin-concentrating-hormone-receptor-2 gene as a risk factor for bipolar affective disorder. Am J Med Genet B Neuropsychiatr Genet (2010) 0.76
Leukemia inhibitory factor differentially regulates capsaicin and heat sensitivity in cultured rat dorsal root ganglion neurons. Neuropeptides (2008) 0.76
Age-modulated association between prefrontal NAA and the BDNF gene. Int J Neuropsychopharmacol (2012) 0.75